Acalabrutinib

TypeName: Business Offer
Category:
Offer Date:2019/05/22
Country: United States
Summary: Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. https://www.bocsci.com/acalabrutinib-cas-1420477-60-6-item-470855.html
Description:
OfferId: 4240
Name:Alex Brown
Telphone:
Categories